Table 4

ELDQOL mean scores, SDs and 95% CIs with T1–T3 adjusted for baseline

NControl groupNIntervention group
MeanSD95% CIsMeanSD95% CIsEffect size of the group difference (80% CI)
ELDQOL seizure severity
 T0 (baseline)1227.508.291129.259.37
 T1 (4 weeks)1026.4222.46 to 30.39826.6622.50 to 30.820.04* (−0.17 to 0.25)
 T2 (12 weeks)1124.2620.27 to 28.25929.1725.01 to 33.330.79* (0.43 to –1.15)
 T3 (20 weeks)1325.6221.68 to 29.56827.0622.68 to 31.440.21* (−0.02 to 0.44)
ELDQOL side effects
 T0 (baseline)1171.564.931565.9910.75
 T1 (4 weeks)1265.6650.02 to 72.291765.9860.84 to 71.120.03* (−0.13 to 0.19)
 T2 (12 weeks)1366.5760.10 to 73.051565.1559.84 to 70.460.12† (−0.06 to –0.30)
 T3 (20 weeks)1164.5457.65 to 71.431464.8759.60 to 70.140.03* (−0.14 to –0.20)
ELDQOL behaviour
 T0 (baseline)1914.363.252115.965.33
 T1 (4 weeks)1515.4813.92 to 17.031914.6713.29 to 16.060.26† (0.07 to 0.45)
 T2 (12 weeks)1514.3912.83 to 15.951615.2513.78 to 16.710.28* (0.08 to 0.48)
 T3 (20 weeks)1615.8614.33 to 17.391614.5013.03 to 15.960.43† (0.21 to –0.65)
ELDQOL mood
 T0 (baseline)1928.276.102030.727.31
 T1 (4 weeks)1531.0728.73 to 33.421829.5327.34 to 31.710.32† (0.12 to 0.52)
 T2 (12 weeks)1530.6428.27 to 33.001631.6229.32 to 33.930.21* (0.02 to 0.40)
 T3 (20 weeks)1631.0828.78 to 33.381730.0527.85 to 32.240.22† (0.04 to 0.40)
  • Higher scores reflect poorer quality of life.

  • *Effect size in favour of the control group.

  • †Effect size in favour of the intervention group.

  • ELDQOL, Epilepsy and Learning Disabilities Quality of Life Scale.